<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01950104</url>
  </required_header>
  <id_info>
    <org_study_id>IVISEV-005VINCI</org_study_id>
    <nct_id>NCT01950104</nct_id>
  </id_info>
  <brief_title>Day 3 Embryo Biopsy Versus Blastocyst Biopsy in PGS Cases</brief_title>
  <acronym>VINCI</acronym>
  <official_title>Comparative Study Between Day 3 Embryo Biopsy and Blastocyst Biopsy in Preimplantation Genetic Screening Cases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IVI Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preimplantation genetic diagnosis (PGS) is a technique that allow us to improve the results&#xD;
      of assisted reproduction techniques through the selection of embryos free of chromosomal&#xD;
      abnormalities.&#xD;
&#xD;
      At present, it has not been proved that the usage of PGS really improves the live birth rate&#xD;
      in IVF cycles. However, it has been stated that the reason of not having better results when&#xD;
      using PGS is that the methodology applied is not adequate.&#xD;
&#xD;
      Several authors propose that the optimal methodology for PGS includes the application of&#xD;
      comparative genomic hybridization (CGH) arrays for genetic testing and carrying out embryo&#xD;
      biopsy at the blastocyst stage. Nevertheless, most IVF centres still applies the day 3 embryo&#xD;
      biopsy as a daily routine. Despite this fact, there is a gradual transition towards the usage&#xD;
      of blastocyst-stage biopsy instead of day 3 biopsy.&#xD;
&#xD;
      The purpose of this clinical study is analysing the results of the IVF cycles with embryo&#xD;
      biopsy for PGS. Live birth rates and other parameters as the pregnancy and implantation rates&#xD;
      together with embryo quality will be analysed and compared between two groups of patients&#xD;
      undergoing IVF cycles with PGS. In one group the biopsy will be applied in day 3 of the&#xD;
      embryo development, while in the other group the embryo biopsy will be fulfilled at the&#xD;
      blastocyst stage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No started, lack of funding&#xD;
  </why_stopped>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>20 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo quality</measure>
    <time_frame>1 year</time_frame>
    <description>Day 3 embryo quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>20 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Infertility</condition>
  <condition>Embryo Biopsy</condition>
  <arm_group>
    <arm_group_label>Day 3 embryo biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Embryo biopsy is applied at day 3 of the embryo development</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blastocyst biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Embryo biopsy is applied at the blastocyst stage of the embryo development (day 5 or 6)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Day 3 embryo biopsy</intervention_name>
    <description>Embryo biopsy is applied at day 3 of the embryo development.</description>
    <arm_group_label>Day 3 embryo biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blastocyst biopsy</intervention_name>
    <description>Embryo biopsy is applied at the blastocyst stage of the embryo development</description>
    <arm_group_label>Blastocyst biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients under 49 years undergoing IVF cycles with PGS for one of the following reasons:&#xD;
&#xD;
          -  Advanced maternal age&#xD;
&#xD;
          -  Recurrent implantation failure&#xD;
&#xD;
          -  Recurrent abortion&#xD;
&#xD;
          -  Severe male-factor infertility&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not being able to sign the informed consent to participate in the study&#xD;
&#xD;
          -  Patients undergoing preimplantation genetic diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IVI Sevilla</name>
      <address>
        <city>Seville</city>
        <zip>41006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 23, 2013</study_first_submitted>
  <study_first_submitted_qc>September 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2013</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Embryo biopsy</keyword>
  <keyword>Blastocyst stage</keyword>
  <keyword>Day 3</keyword>
  <keyword>Preimplantation genetic screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

